115 related articles for article (PubMed ID: 15142676)
1. In vivo reversal of doxorubicin resistance by (-)-epigallocatechin gallate in a solid human carcinoma xenograft.
Zhang Q; Wei D; Liu J
Cancer Lett; 2004 May; 208(2):179-86. PubMed ID: 15142676
[TBL] [Abstract][Full Text] [Related]
2. Reversal of cancer multidrug resistance by green tea polyphenols.
Mei Y; Qian F; Wei D; Liu J
J Pharm Pharmacol; 2004 Oct; 56(10):1307-14. PubMed ID: 15482646
[TBL] [Abstract][Full Text] [Related]
3. Modulation of P-glycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells.
Qian F; Wei D; Zhang Q; Yang S
Biomed Pharmacother; 2005 Apr; 59(3):64-9. PubMed ID: 15795098
[TBL] [Abstract][Full Text] [Related]
4. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer.
Liang G; Tang A; Lin X; Li L; Zhang S; Huang Z; Tang H; Li QQ
Int J Oncol; 2010 Jul; 37(1):111-23. PubMed ID: 20514403
[TBL] [Abstract][Full Text] [Related]
5. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
Jin J; Wang FP; Wei H; Liu G
Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274
[TBL] [Abstract][Full Text] [Related]
6. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide--doxorubicin conjugate in vitro and in vivo.
Ren Y; Wang Y; Zhang Y; Wei D
Mol Pharm; 2008; 5(4):579-87. PubMed ID: 18461970
[TBL] [Abstract][Full Text] [Related]
7. Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells.
Wen Y; Zhao RQ; Zhang YK; Gupta P; Fu LX; Tang AZ; Liu BM; Chen ZS; Yang DH; Liang G
Oncotarget; 2017 May; 8(18):29760-29770. PubMed ID: 28423656
[TBL] [Abstract][Full Text] [Related]
8. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
Yoshimoto Y; Kawada M; Ikeda D; Ishizuka M
Int Immunopharmacol; 2005 Feb; 5(2):281-8. PubMed ID: 15652759
[TBL] [Abstract][Full Text] [Related]
9. Proanthocyanidin from grape seeds enhances doxorubicin-induced antitumor effect and reverses drug resistance in doxorubicin-resistant K562/DOX cells.
Zhang XY; Li WG; Wu YJ; Bai DC; Liu NF
Can J Physiol Pharmacol; 2005 Mar; 83(3):309-18. PubMed ID: 15870845
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.
Lee ES; Na K; Bae YH
J Control Release; 2005 Mar; 103(2):405-18. PubMed ID: 15763623
[TBL] [Abstract][Full Text] [Related]
11. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
12. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent.
Landis-Piwowar KR; Huo C; Chen D; Milacic V; Shi G; Chan TH; Dou QP
Cancer Res; 2007 May; 67(9):4303-10. PubMed ID: 17483343
[TBL] [Abstract][Full Text] [Related]
13. [MDR-reversing effect of two components of catechin on human hepatocellular carcinoma BEL-7404/Adr in vitro].
Liang G; Zhang S; Huang ZM; Tang AZ
Ai Zheng; 2004 Apr; 23(4):401-5. PubMed ID: 15087027
[TBL] [Abstract][Full Text] [Related]
14. In vitro reversal MDR of human carcinoma cell line by an antisense oligodeoxynucleotide-doxorubicin conjugate.
Ren Y; Zhan X; Wei D; Liu J
Biomed Pharmacother; 2004 Nov; 58(9):520-6. PubMed ID: 15511610
[TBL] [Abstract][Full Text] [Related]
15. Reversal of doxorubicin resistance by guggulsterone of Commiphora mukul in vivo.
Xu HB; Shen ZL; Fu J; Xu LZ
Phytomedicine; 2014 Sep; 21(11):1221-9. PubMed ID: 25172783
[TBL] [Abstract][Full Text] [Related]
16. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
17. In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11-2933.
Alaoui-Jamali MA; Schecter RL; Rustum YM; Centurioni MG; Lehnert S; Batist G
J Pharmacol Exp Ther; 1993 Mar; 264(3):1299-304. PubMed ID: 8450465
[TBL] [Abstract][Full Text] [Related]
18. Advantage of in vivo chemosensitivity assay to detect vincristine-resistance in a human epidermoid carcinoma xenograft.
Abe Y; Yamazaki H; Oshika Y; Suto R; Tsugu A; Ota E; Satoh H; Ohnishi Y; Yanagawa T; Ueyama Y; Tamaoki N; Nakamura M
Anticancer Res; 1996; 16(2):729-34. PubMed ID: 8687121
[TBL] [Abstract][Full Text] [Related]
19. The activity against Ehrlich's ascites tumors of doxorubicin contained in self assembled, cell receptor targeted nanoparticle with simultaneous oral delivery of the green tea polyphenol epigallocatechin-3-gallate.
Ray L; Kumar P; Gupta KC
Biomaterials; 2013 Apr; 34(12):3064-76. PubMed ID: 23357370
[TBL] [Abstract][Full Text] [Related]
20. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
